# Nanjing Leads Biolabs Co.,Ltd clinical trials: 20 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials with Nanjing Leads Biolabs Co.,Ltd as lead sponsor, 13 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Nanjing Leads Biolabs Co.,Ltd: 20 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/nanjing-leads-biolabs-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 13
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 28, 2026 | NCT07791758 | A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma | Nanjing Leads Biolabs Co.,Ltd | Phase 1/2 | Recruiting | Metastatic Colorectal Carcinoma | 369 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791758) |
| July 22, 2026 | NCT07720193 | A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC | Nanjing Leads Biolabs Co.,Ltd | Phase 3 | Not yet recruiting | Advanced Extrapulmonary Neuroendocrine Carcinoma | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07720193) |
| February 5, 2026 | NCT07390383 | A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour\[Substudy 04\] | Nanjing Leads Biolabs Co.,Ltd | Phase 2 | Recruiting | Advanced Solid Tumour | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07390383) |
| January 9, 2026 | NCT07331155 | A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour\[Substudy 03(ESCC)\] | Nanjing Leads Biolabs Co.,Ltd | Phase 2 | Recruiting | Advanced Solid Tumour | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07331155) |
| January 7, 2026 | NCT07323173 | A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus | Nanjing Leads Biolabs Co.,Ltd | Phase 1 | Recruiting | Systemic Lupus Erythematosus | 117 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07323173) |
| December 15, 2025 | NCT07281976 | A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer | Nanjing Leads Biolabs Co.,Ltd | Phase 1/2 | Recruiting | Triple Negative Breast Cancer | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07281976) |
| August 8, 2025 | NCT07111546 | A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours\[Substudy 02(BTC&HCC)\] | Nanjing Leads Biolabs Co.,Ltd | Phase 2 | Recruiting | Advanced Solid Tumour | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07111546) |
| August 1, 2025 | NCT07099430 | A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma. | Nanjing Leads Biolabs Co.,Ltd | Phase 1/2 | Recruiting | Advanced Melanoma | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07099430) |
| June 29, 2025 | NCT07042802 | A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer | Nanjing Leads Biolabs Co.,Ltd | Phase 1/2 | Recruiting | Ovarian Cancer | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07042802) |
| January 20, 2025 | NCT06783647 | A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours\[Substudy 01(NSCLC)\] | Nanjing Leads Biolabs Co.,Ltd | Phase 2 | Recruiting | Advanced Solid Tumour | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06783647) |
| December 6, 2023 | NCT06157827 | A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma | Nanjing Leads Biolabs Co.,Ltd | Phase 1/2 | Recruiting | Advanced Neuroendocrine Carcinoma | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06157827) |
| September 22, 2023 | NCT06049290 | A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma | Nanjing Leads Biolabs Co.,Ltd | Phase 1/2 | Recruiting | Relapsed/Refractory Multiple Myeloma | 342 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06049290) |
| March 22, 2023 | NCT05779163 | A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors | Nanjing Leads Biolabs Co.,Ltd | Phase 1/2 | Completed | Advanced Malignant Tumors | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05779163) |
| August 26, 2022 | NCT05516914 | A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors | Nanjing Leads Biolabs Co.,Ltd | Phase 1/2 | Completed | Malignant Tumors | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05516914) |
| February 3, 2022 | NCT05223231 | Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors | Nanjing Leads Biolabs Co.,Ltd | Phase 1/2 | Completed | Advanced Malignant Tumors | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05223231) |
| December 28, 2021 | NCT05170958 | A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors | Nanjing Leads Biolabs Co.,Ltd | Phase 1/2 | Recruiting | Advanced Solid Tumor | 396 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05170958) |
| November 4, 2021 | NCT05107011 | Phase I/II Clinical Trial of LBL-015 for Injection | Nanjing Leads Biolabs Co.,Ltd | Phase 1/2 | Completed | Advanced Malignant Tumor | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05107011) |
| November 1, 2021 | NCT05102006 | A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors | Nanjing Leads Biolabs Co.,Ltd | Phase 1/2 | Completed | Advanced Malignant Tumors | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05102006) |
| September 13, 2021 | NCT05042908 | Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies | Nanjing Leads Biolabs Co.,Ltd | Phase 1 | Completed | Advanced Malignant Tumor | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05042908) |
| November 23, 2020 | NCT04640545 | A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma | Nanjing Leads Biolabs Co.,Ltd | Phase 1 | Completed | Advanced Melanoma | 79 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04640545) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 3 |
| Phase 1/2 | 12 |
| Phase 2 | 4 |
| Phase 3 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 12 |
| Completed | 7 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasms | 1 |
| Colorectal Neoplasms | 1 |
| Lupus Erythematosus, Systemic | 1 |
| Ovarian Neoplasms | 1 |
| Triple Negative Breast Neoplasms | 1 |
| Multiple Myeloma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Gastropubs in the United States](https://specstream.ai/data/businesses/gastropubs/united-states)
- [Sheet metal fabricators in the United States](https://specstream.ai/data/businesses/sheet-metal-fabricators/united-states)
- [Computer wholesalers in the United States](https://specstream.ai/data/businesses/computer-wholesalers/united-states)
- [Occupational medicine clinics in the United States](https://specstream.ai/data/businesses/occupational-medicine-clinics/united-states)
- [Automation companies in the United States](https://specstream.ai/data/businesses/automation-companies/united-states)
- [Hospices in the United States](https://specstream.ai/data/businesses/hospices/united-states)
